$0.44
(Market cap
$49 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
34.6
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
8,891,951
10 Years Aggregate
CFO
$-64.91 Mln
EBITDA
$-72.69 Mln
Net Profit
$-74.73 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Edesa Biotech (EDSA)
| 297.9 | -65.3 | -18.1 | 197.4 | -3.6 | -32.6 | -39.5 |
|
BSE Sensex*
| -11.8 | -1.8 | -2.9 | -9.5 | 6.0 | 7.3 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Edesa Biotech (EDSA)
| -15.5 | -69.8 | -61.6 | 32.5 | 3.7 | -24.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Edesa Biotech (EDSA)
|
5.7 | 48.6 | 0.1 | -10.4 | -20,782.3 | -92.2 | -- | 34.6 |
| 5.3 | 1,716.2 | 79.2 | -144.0 | -259.5 | -15.1 | -- | 2.1 | |
| 15.9 | 2,037.1 | 298.3 | 298.2 | 47.7 | 63.9 | 7.3 | 3.7 | |
| 5.5 | 303.9 | 0.0 | -35.1 | 131,201.1 | -71 | -- | 6.4 | |
| 8.9 | 302.2 | 51.0 | -8.4 | -13.3 | -- | -- | 8.4 | |
| 1.6 | 5.2 | 663.9 | -9.9 | -1.5 | -86 | -- | 0.8 | |
| 1.3 | 153.1 | 1.8 | -68.4 | -3,544.8 | -241.8 | -- | 4.4 | |
| 52.2 | 5,000.5 | 0.0 | -383.2 | -- | -40.4 | -- | 3.7 |
Shareholding Pattern
View DetailsAbout Edesa Biotech (EDSA)
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal... antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. Read more
-
CEO, Company Secretary & Director
Dr. Pardeep Nijhawan FRCPC, M.D.
-
CEO, Company Secretary & Director
Dr. Pardeep Nijhawan FRCPC, M.D.
-
Headquarters
Markham, ON
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Edesa Biotech (EDSA)
What is the current share price of Edesa Biotech Inc (EDSA) Today?
The share price of Edesa Biotech Inc (EDSA) is $5.65 (NASDAQ) as of 11-Jun-2026 16:20 EDT. Edesa Biotech Inc (EDSA) has given a return of -3.56% in the last 3 years.
What is the current PB & PE ratio of Edesa Biotech Inc (EDSA)?
Since, TTM earnings of Edesa Biotech Inc (EDSA) is negative, P/E ratio is not available.
The P/B ratio of Edesa Biotech Inc (EDSA) is 34.60 times as on 05-Jun-2026, a 748 premium to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.06
|
1.19
|
|
2024
|
-2.16
|
6.74
|
|
2023
|
-0.23
|
0.27
|
|
2022
|
-0.10
|
0.20
|
|
2021
|
-1.11
|
1.13
|
What is the 52 Week High and Low of Edesa Biotech Inc (EDSA)?
The 52-week high and low of Edesa Biotech Inc (EDSA) are Rs 20.32 and Rs 0.72 as of 12-Jun-2026.
What is the market cap of Edesa Biotech Inc (EDSA)?
Edesa Biotech Inc (EDSA) has a market capitalisation of $ 49 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Edesa Biotech Inc (EDSA)?
Before investing in Edesa Biotech Inc (EDSA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.